SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Milnacipran Phase 3 Results and FDA Decision Should Move Forest Labs Off Lows
FRX
|
|
|
<> 
Since I last wrote about Cypress Bioscience (CYPB) two months ago , the stock has moved lower with the Company now trading even closer to its net cash position of $4 per share with a closing price on Friday of $6.43 per share. The level of short interest has remained steady this year and is still high at 6.6 million shares compared to a float of about 32 million shares and average volume that is just over 300,000 shares per day. Most of the options action in Cypress Bio is...
|
strong third quarter results
FRX
|
|
|
Forest Labs ( FRX ) Forest Labs ( FRX ) shares have put on quite a performance in 2008, as strong third quarte results have propelled the company's stock price sharply higher in a very challenging market environment. On Jan 15, Forest Labs reported that its third quarter revenue grew 12% to $998.2, while net income jumped 20% to $301.8 million, from the same period last year. Investors obviously liked the results, sending its share price rocketing higher. Since the great report, shares have been pressuring a key area of resistance just above $41. Shares have broke...
|
Buy Forest Labs (FRX) and get 16% compounded annual return
FRX
|
|
|
Forest Labs (FRX) develops and makes branded and generic ethical drug products. It products include Lexapro, a single isomer version of Celexa for the treatment of major depression and generalized anxiety disorder; Namenda, N-methyl-D-aspartate antagonist for the treatment of moderate to severe Alzheimer's disease; Benicar, an angiotensin receptor blocker for the treatment of hypertension, and
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Forest Laboratories Inc
- Answers.com
